Engineering
Living Medicines
for Chronic Diseases

We don’t discover drugs.

We build them.

The future of medicine is cellular. We engineer cell therapies to outsmart chronic diseases. Therapies that are precise, extensible, and act symbiotically with the patient to achieve long-term health. Beyond smart, our therapies are alive.

We don’t discover drugs.

We build them.

The future of medicine is cellular. We engineer cell therapies to outsmart chronic diseases. Therapies that are precise, extensible, and act symbiotically with the patient to achieve long-term health. Beyond smart, our therapies are alive.

GEMMs: Genetically Engineered Microbial Medicines

The first platform for colonizing the gut with engineered microbes.

The microbes in our gut are living pharmacies, producing and consuming many molecules that impact our health. Novome’s unique synthetic biology tools allow us to plug into this ecosystem and deliver precise activities to treat chronic diseases.

Founded on pioneering technology from Stanford University, our proprietary platform enables controllable engraftment of GEMMs in the gut for sustained and truly effective therapies.

Engineered

We engineer bacterial strains to perform therapeutic functions to address a wide variety of diseases

Colonizing

Our microbes colonize the gut for an extended period of time at a predictable abundance

Controllable

Colonization is maintained and tuned with a daily dose of a prebiotic polysaccharide

Engineered

We engineer bacterial strains to perform therapeutic functions to address a wide variety of diseases

Colonizing

Our microbes colonize the gut for an extended period of time at a predictable abundance

Controllable

Colonization is maintained and tuned with a daily dose of a prebiotic polysaccharide

Our Advantages

The Ideal Modality for Treating Chronic Diseases

Chronic diseases are complicated. Treatment shouldn’t be.

Novome’s platform addresses areas where current therapeutic approaches struggle, enabling multiple targets to be engaged in a dynamic fashion with simple, non-invasive dosing. Manufacturing an intelligent, universal therapeutic is possible with GEMMs.

Well-defined Mechanisms of Action

Our therapies utilize well-studied, highly-abundant gut microbes, programmed with targeted therapeutic activities.

Tunable Treatment

Treatment is tailored to specific conditions by tuning expression of each therapeutic activity.

Convenient Delivery

GEMMs are designed to controllably expand in the gut of any patient, enabling small, oral doses of a universal strain.

Safe and Non-invasive

The gut is our body’s natural interface with foreign cells, making it the ideal site to deploy long-term cell therapies.

Pipeline

The path to living medicines.

Our pipeline targets a variety of diseases based on clinical need and regulatory endpoints. Our programs focus on diseases with clear, mechanistic etiology that are readily addressed with defined activities.

Our lead program, enteric hyperoxaluria, is a leading cause of kidney stones and affects hundreds of thousands of people in the US alone. We’ve developed a therapeutic strain that breaks down oxalate before it can be absorbed.

IndicationsPhase
DiscoveryPreclinicalIND-EnablingPhase 1Phase 2
Enteric Hyperoxaluria
Phase 1
Irritable Bowel Syndrome
Preclinical
Ulcerative Colitis
Discovery
Immuno Oncology
Discovery
Enteric Hyperoxaluria
Irritable Bowel Syndrome
Ulcerative Colitis
Immuno Oncology

Our People

Blake Wise
CEO
Will DeLoache
Will DeLoache
CSO, Co-Founder
Lachy McLean
CMO
Wes Whitaker
Weston Whitaker
VP of Research, Co-Founder
Liz Shepard
Liz Shepherd
Head of People, 
Co-Founder
Zachary Russ
Zachary Russ
Principal Scientist, Co-Founder
Ali Akin
Scientist
Domenique Banta
Domenique Banta
Research Associate
Brooks Bond-Watts
Senior Scientist
Polina Bukshpun
AD, Clinical Operations
Areta Buness
Research Associate
Jake Flood
Scientist
Clare Gill
Clare Gill
Manager, Strain Engineering
Chris Godfrey
Controller
Janeth Godoy
Research Associate
Ada Huang
Research Associate
Sonia Jaidka
Research Associate
Cynde Jones
EA, Office Manager
Se Kim
Research Assistant
Kathy Lam
Scientist
Mike Lee
AD, Informatics
Alexander Louie
Scientist
Coyote Marin
Senior Software Engineer
Lindsay Piette
Research Associate
Lauren Popov
AD, Translational Biology
Leo Ramirez
Research Associate
Vanessa Ridaura
AD, Microbiology & Immunology
Harneet Rishi
Harneet Rishi
Scientist
Ricky Robinson
Research Associate
Peter Spanogiannopoulos
Scientist
Jessica Tan
Research Associate
Tariq Warsi
Head of Tech Ops
Lane Weaver
Lane Weaver
Head of Business Development
David Zong
Scientist
Kiersten Stead, PhD
Board of Directors
Andy Schwab
Andy Schwab
Board of Directors
Dan Janney
Board of Directors
Zachary Hornby
Board of Directors
Dave Cook, PhD
Board of Directors
MIra Chaurushiya
Mira Chaurushiya, PhD
Board Observer
Justin Sonnenburg
Justin Sonnenburg, PhD
Co-Founder, Scientific Advisory Board
John Dueber
John Dueber, PhD
Scientific Advisory Board
Alan Pao
Alan Pao, MD
Scientific Advisory Board
Eric Martens, PhD
Scientific Advisory Board

Investors

Careers

At Novome, we are looking for curious and creative people to join our team. Those willing to question the status quo to drive the future of precision therapeutics.

We are located just off the Bay Trail in South San Francisco.

Open Positions
 

Careers

At Novome, we are looking for curious and creative people to join our team. Those willing to question the status quo to drive the future of precision therapeutics.

We are located just off the Bay Trail in South San Francisco.

Open Positions